
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
PAREXEL, an innovator of global biopharmaceutical services, announced a new collaboration with Eli Lilly and Company to launch a clinical research learning and development program in China which will bring training opportunities to China’s clinical trial sites and investigators.
Read the full release






